A Phase 2 interventional study of Semaglutide and Placebo in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 130 sites in 5 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 61st largest by enrollment, is one of 18 that started in 2022, is one of 10 in phase 2, and was the 103rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Emory University · Sites in United States
Ages 65+ · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 14 · Phase 3 58 · Phase 4 40
First in 2007; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 104 across the 163 interventional studies. Of the 109 that completed or were terminated, 54 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 163 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 197th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2022, is one of 37 in phase 2, and was the 566th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
14 of the studies testing semaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06461377The First Affiliated Hospital with Nanjing Medical UniversityThe Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide [2 milligrams (mg), 8 mg, or 16 mg] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen called NovoPen®4. The injection pen is a medical tool with a needle used to inject the study medicine under the skin. The study will last for about 52 weeks. Participants will have 13 clinic visits and 4 phone calls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.
Drug: Semaglutide
Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.
Drug: Placebo
Participants will receive once-weekly semaglutide 8 mg s.c. injection.
Drug: Semaglutide
Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.
Drug: Placebo
Participants will receive once-weekly semaglutide 16 mg s.c. injection.
Drug: Semaglutide
Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.
Drug: Placebo
Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
Change in Glycated Haemoglobin (HbA1c)
Change in HbA1c from baseline (week 0) to end of treatment (week 40) is presented.
Time frame: Baseline (week 0) and End of treatment (week 40)
Change in Body Weight
Change in body weight from baseline (week 0) to end of treatment (week 40) is presented.
Time frame: Baseline (week 0) and End of treatment (week 40)
Number of Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant that is temporally associated with use of investigational medicinal products (IMP), whether or not considered related to IMP. AE can therefore be any unfavourable \& unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with use of IMP. TEAE was defined as event that had onset date (or increase in severity) during on-treatment observation period. On treatment observation period data are presented. On-treatment observation period is defined as time points from first drug date until first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until first date of end of study visit or date of death or date of withdrawal of informed consent or contact as defined by investigator for participants that are lost to follow up.
Time frame: From baseline (week 0) up to end of study (week 49)
Number of Treatment-emergent Severe Hypoglycaemic Episodes
Number of treatment-emergent severe Hypoglycaemic episodes are presented. Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. On treatment observation period data are presented. On-treatment oberservation period is defined as time points from first drug date until the first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until the first date of end of study visit or date of death or date of withdrawal of informed consent or date of last contact as defined by investigator for participants that are lost to follow up.
Time frame: From baseline (week 0) up to end of study (week 49)
This study was conducted at 82 active sites in 4 countries, of which 75 sites enrolled participants.
| Milestone | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo |
|---|---|---|---|---|
| Started | 61 | 62 | 62 | 60 |
| Full analysis set | 61 | 62 | 62 | 60 |
| Safety analysis set | 60 | 60 | 62 | 59 |
| Completed | 56 | 54 | 55 | 54 |
| Not completed | 5 | 8 | 7 | 6 |
| Withdrew: Withdrawal by subject | 1 | 5 | 4 | 3 |
| Withdrew: Lost to follow-up | 4 | 2 | 2 | 2 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 |
| Withdrew: Failure to meet randomization criteria | 0 | 0 | 0 | 1 |
Change in HbA1c from baseline (week 0) to end of treatment (week 40) is presented.
| Percentage-point of HbA1c | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo |
|---|---|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -1.9 ± 1.1 | -1.8 ± 1.5 | -2.1 ± 1.5 | -1.1 ± 1.3 |
Change in body weight from baseline (week 0) to end of treatment (week 40) is presented.
| Kilogram (kg) | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo |
|---|---|---|---|---|
| Change in Body Weight | -8.9 ± 8.5 | -10.1 ± 7.4 | -13.1 ± 8.4 | -2.3 ± 4.9 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant that is temporally associated with use of investigational medicinal products (IMP), whether or not considered related to IMP. AE can therefore be any unfavourable \& unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with use of IMP. TEAE was defined as event that had onset date (or increase in severity) during on-treatment observation period. On treatment observation period data are presented. On-treatment observation period is defined as time points from first drug date until first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until first date of end of study visit or date of death or date of withdrawal of informed consent or contact as defined by investigator for participants that are lost to follow up.
| Events | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo |
|---|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) | 43 | 54 | 55 | 37 |
Number of treatment-emergent severe Hypoglycaemic episodes are presented. Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. On treatment observation period data are presented. On-treatment oberservation period is defined as time points from first drug date until the first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until the first date of end of study visit or date of death or date of withdrawal of informed consent or date of last contact as defined by investigator for participants that are lost to follow up.
| Episodes | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo |
|---|---|---|---|---|
| Number of Treatment-emergent Severe Hypoglycaemic Episodes | 0 | 0 | 0 | 0 |
Collected over From baseline (week 0) up to end of study (week 49). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide 2.0 mg | 0/60 (0%) | 4/60 (6.7%) | 30/60 (50%) |
| Semaglutide 8.0 mg | 0/60 (0%) | 2/60 (3.3%) | 48/60 (80%) |
| Semaglutide 16.0 mg | 0/62 (0%) | 1/62 (1.6%) | 50/62 (80.6%) |
| Placebo | 0/59 (0%) | 2/59 (3.4%) | 29/59 (49.2%) |
| Event | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo |
|---|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 0/60 | 0/60 | 0/62 | 1/59 |
| VertigoEar and labyrinth disorders | 0/60 | 0/60 | 0/62 | 1/59 |
| Cardiac failure chronicCardiac disorders | 0/60 | 1/60 | 0/62 | 0/59 |
| Incisional herniaInjury, poisoning and procedural complications | 1/60 | 0/60 | 0/62 | 0/59 |
| Inguinal herniaGastrointestinal disorders | 0/60 | 1/60 | 0/62 | 0/59 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/60 | 0/60 | 0/62 | 0/59 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/60 | 0/60 | 0/62 | 0/59 |
| Vestibular neuronitisInfections and infestations | 1/60 | 0/60 | 0/62 | 0/59 |
| Cholecystitis acuteHepatobiliary disorders | 0/60 | 0/60 | 1/62 | 0/59 |
| Event | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 13/60 | 25/60 | 23/62 | 9/59 |
| DiarrhoeaGastrointestinal disorders | 9/60 | 20/60 | 13/62 | 7/59 |
| VomitingGastrointestinal disorders | 11/60 | 14/60 | 16/62 | 4/59 |
| ConstipationGastrointestinal disorders | 2/60 | 8/60 | 12/62 | 3/59 |
| HeadacheNervous system disorders | 2/60 | 6/60 | 7/62 | 8/59 |
| COVID-19Infections and infestations | 1/60 | 8/60 | 1/62 | 3/59 |
| DizzinessNervous system disorders | 2/60 | 6/60 | 3/62 | 4/59 |
| Back painMusculoskeletal and connective tissue disorders | 1/60 | 0/60 | 6/62 | 2/59 |
| FatigueGeneral disorders | 2/60 | 4/60 | 6/62 | 2/59 |
| Abdominal pain upperGastrointestinal disorders | 5/60 | 5/60 | 2/62 | 3/59 |
| Age, Continuous(years) | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 52.3 ± 7.6 | 53.7 ± 7.5 | 52.9 ± 8.6 | 52.1 ± 9.5 | 52.8 ± 8.3 |
| Sex: Female, Male(Participants) | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 27 | 33 | 25 | 35 | 120 |
| Male | 34 | 29 | 37 | 25 | 125 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 9 | 13 | 39 |
| Not Hispanic or Latino | 52 | 54 | 53 | 47 | 206 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Semaglutide 2.0 mg | Semaglutide 8.0 mg | Semaglutide 16.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 11 | 4 | 4 | 25 |
| White | 54 | 49 | 56 | 55 | 214 |
| More than one race | 0 | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
Showing the first 100 of 130 sites across 5 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Aug 2022 to primary completion in Oct 2023, 14 months.
Results were first posted in Nov 2024, 1 year after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 14 months is close to that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide